Sirolimus gel for raised, dark birthmarks
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This pilot study tests a gel called sirolimus to see if it can safely shrink or improve raised, dark birthmarks (epidermal nevi) in people 6 and older. The gel is applied directly to the birthmark, and the study will check how well it works and if it causes any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 6 years old or older.
- You need to have an epidermal nevus (a type of birthmark) that is not inflamed.
- The birthmark must have been there for at least 3 years and been stable.
- The birthmark must be at least 2 centimeters long (can add up smaller ones if they are close together).
- The birthmark must be raised and darker than the skin around it.
- You must avoid using moisturizers on the birthmark during the study, and not shower or bathe for 2 hours after applying the gel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
This trial tests a topical gel (a cream you apply to skin) containing sirolimus to treat angiokeratomas, which are small growths on the skin. The goal is to see if this treatment is safe and effective.
This trial studies whether taking sirolimus once a week can improve blood vessel, lymph vessel, or mixed (venolymphatic) malformations. It may help reduce symptoms and lesion size, while also monitoring safety in children and adults.
This study compares three approaches—pulsed-dye laser, timolol (a medicated skin solution), or watch-and-wait—to see which works best to slow the growth of a hemangioma birthmark in young babies. It may help find a treatment that shrinks or controls the birthmark as early as possible.
This study tests a new gel called LUT017 to see if it helps skin wounds heal better and faster after removal of harmless skin spots (like moles). It is for healthy adults having at least two benign skin lesions removed, and the gel is applied to the wounds to improve healing.
This study tests whether a topical drug called SADBE, applied to a congenital mole (a birthmark), can help reduce the mole before surgery. It is an early-stage trial, so it will help us learn if the treatment is safe and works.
Hear when a new Epidermal Nevi trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.